Most researchers seeking out CJC-1295 in Midar immediately realize that local retail options are all but absent from local stores. The practical takeaway for Midar researchers: sourcing CJC-1295 hinges on vendor quality evaluation, not geography — and the evaluation methodology is universal across all locations. A legitimate CJC-1295 supplier's COA must contain HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all traceable to your specific batch. This guide guides Midar researchers through that evaluation process and explains how to verify CJC-1295 vendor quality step by step.
CJC-1295: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Midar comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
CJC-1295 Purchasing Guide
The most consistent path to quality CJC-1295 is engaging research communities before vendor sites — peptide forums aggregate real purchasing experience that are more trustworthy than marketing materials. When reviewing a CJC-1295 COA, verify: the batch number corresponds to your vial, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are below the threshold for research use. The combination of peer feedback and direct document verification is the most reliable sourcing approach — community feedback surfaces recurring issues no single purchase reveals, and vice versa. Store lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the volume needed for upcoming use and return unused portion to the freezer.
Order CJC-1295 — ships to Midar
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and limited human studies. Proper handling of CJC-1295 requires careful sterile procedure — alcohol-swabbed septum, fresh needles, clean working environment — and temperature control throughout the entire workflow. Bacterial endotoxin contamination is the greatest safety hazard unique to this class of compound — verify endotoxin testing is included in the batch-specific COA before any injectable research application. Researchers running multi-compound protocols with CJC-1295 should review the available literature for documented interactions before proceeding with any multi-compound protocol.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
